US-based pharmaceutical firm Pfizer has reported positive top-line results from its Phase II study of Clostridium difficile (C. difficile) vaccine PF-06425090 to prevent C. difficile infection (CDI).

PF-06425090 is an investigational vaccine candidate designed with a functional antibody response to neutralise toxins A and B, the two disease-causing toxins generated by C. difficile.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Spore-forming pathogen C. difficile releases toxins that might lead to life-threatening infections such as diarrhea, pseudomembranous colitis, asymptomatic colonisation, toxic megacolon and intestinal perforation.

The randomised, placebo-controlled, observer-blinded Phase II study evaluated the safety, tolerability, and immunogenicity of the vaccine in more than 850 healthy adults aged 65 to 85.

“The randomised, placebo-controlled, observer-blinded Phase II study evaluated the safety, tolerability, and immunogenicity of the vaccine in more than 850 healthy adults aged 65 to 85.”

Pfizer vaccine research and development senior vice-president and head Kathrin Jansen said: “Despite improved infection control measures, C. difficile disease continues to rise, further augmenting an already urgent public health threat with particular negative impact on older adults.

“We are very encouraged by these interim immunogenicity and safety results demonstrating robust increases in vaccine-elicited neutralising antibodies to both toxins, that we believe could provide protection against C. difficile disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study assessed two dose levels 100mcg and 200mcg of the vaccine candidate on two different three-dose vaccination schedules.

Based on the current data from the pre-planned interim analysis, the firm intends to initiate the Phase III trial for the vaccine in the first half of this year.

In August 2014, C. difficile vaccine received fast track designation from the US Food and Drug Administration (FDA).